Dr. Venkat Reddy Thangella has been appointed as Vice President – R&D, Peptides and Small Molecules at Chemeca Drugs Pvt Ltd. In his new role, he will lead the Chemeca Research and Development group, driving innovation in the development of peptide-based therapeutics and pharmaceutical small molecules.
With significant experience in pharmaceutical research and development, Dr. Thangella brings a wealth of expertise spanning both scientific innovation and strategic growth. Prior to joining Chemeca Drugs, he served as Co-Founder and Chief Scientific Officer at ManoTri Pharma Pvt Ltd, where he spearheaded scientific operations and strategic planning. He has also held key leadership roles at Intech Analytical Instruments as Director – Strategic Growth & Scientific Operations, and as Commercial Head at AMSAAL.
Dr. Thangella’s extensive global experience includes leadership positions at Phenomenex as Head of Business Development Group – India, Chief Application Scientist at HanBon Science Technology China, and Research Scientist / Head of API at ISSAR Pharmaceuticals Pvt. Ltd. He has contributed significantly to medicinal chemistry research at SAPALA Organics Pvt Ltd and has held academic roles, including PhD Researcher at Technological University Dublin and Assistant Teaching Staff at Institute of Technology Tallaght Dublin.
Earlier in his career, Dr. Thangella gained valuable experience as a Process Chemist at Pfizer Pharmaceuticals in Ireland and conducted advanced research during his master’s Thesis at the Swedish LCD Research Center AB, Sweden. His multidisciplinary experience in chemistry, pharmaceuticals, and R&D strategy positions him uniquely to lead Chemeca Drugs’s next phase of innovation in peptides and small molecules.
With Dr. Thangella’s appointment, Chemeca Drugs Pvt Ltd strengthens its commitment to cutting-edge pharmaceutical research, expanding its capabilities in peptide therapeutics and small molecule development while fostering scientific excellence.